日韩AV91,久9视频久9久

Roche Full Year 2025 Financial Report Financial statements Roche's 2025 financial results show a 7% sales growth, driven by innovative drugs and diagnostics. Core operating profit rose 13%, with strong performance across key markets. The company remains optimistic for 2026, focusing on sustainable growth.
Roche Clinical Project Termination and TIGIT Abandonment Roche Roche terminates 7 clinical projects including all TIGIT antibody trials, updates 2025 H1 results with strong revenue growth and advances key therapies in oncology, hematology, neurology, immunology, and ophthalmology.
Roche 2025 H1 Financial Report Roche Roche reports 7% growth in H1 2025, with Phesgo up 55% and Polivy up 46%. China revenue rises 9%. Strong gains in hematology, immunology, and ophthalmology offset legacy drug declines.
Chugai Taps Gero's AI in $1B+ Aging R&D Deal Roche Chugai Pharmaceutical teams up with AI biotech Gero in a $1B+ deal to develop antibody therapies targeting aging-related diseases. The partnership leverages Gero’s AI platform and supports Chugai’s global innovation strategy.
Vividion Gains Rights to Covalent WRN Inhibitor VVD-214 from Roche Bayer Bayer’s Vividion Therapeutics secures exclusive global rights to VVD-214, the only clinical-stage covalent WRN inhibitor, from Roche. The drug shows early promise for treating MSI-high cancers in phase 1 trials.
Pharma's $158B U.S. Manufacturing Surge Market Trend Major pharmaceutical companies pledge $158 billion to U.S. manufacturing to sidestep tariff threats, funding facilities from California to North Carolina. Lilly, J&J, Novartis, Roche and Regeneron drive billions in reshoring investments, creating thousands of jobs.
Roche's CD3/CD20 Bispecific Antibody Faces Setback Roche Roche's Columvi faces FDA concerns over insufficient U.S. data in the STARGLO trial for relapsed/refractory DLBCL. Experts question efficacy outside Asia; FDA decision expected July 2025.
Roche Invests 2.04 Billion Yuan in China Capacity News Roche announces a 2.04 billion yuan investment to build a new biopharmaceutical production base in Shanghai, enhancing local drug manufacturing and advancing healthcare innovation in China.
Single Dose of Baloxavir Cuts Household Flu Transmission by 32%: NEJM Study Roche A NEJM study shows that a single dose of Baloxavir (Tamiflu?) reduces household influenza virus transmission by 32%. Backed by Roche, the findings offer new hope for flu prevention and public health impact.
Roche's Q1 2025 Financial report Financial statements Roche Q1 2025 financial results show 6% revenue growth, driven by strong demand for innovative drugs and diagnostics. China leads international growth, while the company makes strategic investments in the US and global R&D.

<Pre12 3 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水